Success Metrics

Clinical Success Rate
89.6%

Based on 60 completed trials

Completion Rate
90%(60/67)
Active Trials
30(17%)
Results Posted
18%(11 trials)
Terminated
7(4%)

Phase Distribution

Ph phase_1
28
16%
Ph phase_2
120
68%
Ph phase_4
5
3%
Ph phase_3
16
9%
Ph not_applicable
3
2%

Phase Distribution

28

Early Stage

120

Mid Stage

21

Late Stage

Phase Distribution172 total trials
Phase 1Safety & dosage
28(16.3%)
Phase 2Efficacy & side effects
120(69.8%)
Phase 3Large-scale testing
16(9.3%)
Phase 4Post-market surveillance
5(2.9%)
N/ANon-phased studies
3(1.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.2%

60 of 73 finished

Non-Completion Rate

17.8%

13 ended early

Currently Active

30

trials recruiting

Total Trials

177

all time

Status Distribution
Active(51)
Completed(60)
Terminated(13)
Other(53)

Detailed Status

Completed60
unknown51
Recruiting23
Not yet recruiting20
Terminated7
Active, not recruiting7

Development Timeline

Analytics

Development Status

Total Trials
177
Active
30
Success Rate
89.6%
Most Advanced
Phase 4

Trials by Phase

Phase 128 (16.3%)
Phase 2120 (69.8%)
Phase 316 (9.3%)
Phase 45 (2.9%)
N/A3 (1.7%)

Trials by Status

unknown5129%
not_yet_recruiting2011%
terminated74%
withdrawn63%
completed6034%
enrolling_by_invitation11%
recruiting2313%
suspended21%
active_not_recruiting74%

Recent Activity

Clinical Trials (177)

Showing 20 of 177 trialsScroll for more
NCT07847710Phase 2

Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial

Recruiting
NCT06730373Phase 2

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Recruiting
NCT07776639Phase 2

Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

Active Not Recruiting
NCT03615326Phase 3

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Completed
NCT07025889Phase 1

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

Recruiting
NCT06447636Phase 2

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

Active Not Recruiting
NCT07745790Phase 2

Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer

Not Yet Recruiting
NCT07733050Phase 2

Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Not Yet Recruiting
NCT06914687Phase 2

Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Active Not Recruiting
NCT07727993Phase 1

Neoadjuvant Propranolol Plus SOX and Toripalimab for Locally Advanced Gastric/GEJ Adenocarcinoma

Not Yet Recruiting
NCT07384234Phase 2

SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis

Recruiting
NCT07621484Phase 2

HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer

Not Yet Recruiting
NCT07685704Phase 2

Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study

Not Yet Recruiting
NCT05026905Phase 2

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

Active Not Recruiting
NCT05144854Phase 3

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Active Not Recruiting
NCT05867121Phase 1

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

Completed
NCT07640048

Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study

Recruiting
NCT07038629Phase 2

Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC

Recruiting
NCT07561775Phase 2

Adebrelimab Plus S-1 for Resected Cholangiocarcinoma

Not Yet Recruiting
NCT06256328Phase 2

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
177